Pharmafile Logo

Antibody drug conjugate

AstraZeneca AZ

CHMP backs AZ’s Lynparza for ovarian cancer maintenance

Studies show that the drug reduced risk of disease progression

- PMLiVE

AbbVie reports more solid data for would-be psoriasis blockbuster

Risankizumab showed to be more effective in plaque psoriasis patients than J&J’s Stelara

Roche Basel Switzerland

Roche to buy cancer data firm Flatiron for $1.9bn

Data provides a wealth of RWE opportunities

Lynch syndrome: a patient perspective

Blue Latitude Health intern Costantino Ciotti gives an insight into life with Lynch Syndrome, a genetic condition associated with colon cancer. Here he explores the patient’s perspective, including treatment options,...

Blue Latitude Health

- PMLiVE

Novartis joins biosimilar Humira push in US

Pharma giant hopes its candidate will follow in the footsteps of Amgen’s Amjevita and BI’s Cyltezo

Roche and GE Healthcare plan ‘industry first’ digital platform

Co-developed clinical decision support software will begin with cancer and critical care

Roche Basel Switzerland

Roche buys cancer company Ignyta for $1.7bn

Pursues same oncology target that encouraged Bayer's recent deal with Loxo

- PMLiVE

AbbVie’s JAK inhibitor upadacitinib clears another phase III trial

Moves a step closer to the rheumatoid arthritis market

- PMLiVE

Lucid picks up rare disease and orphan drugs trophy at PMEA 2017

Judges praised the AbbVie project for its impressive reach

- PMLiVE

AbbVie named PMEA 2017 Company of the Year

Sees off strong competition from Amgen and Sanofi

- PMLiVE

Boehringer claims EU okay for Humira biosimilar

But won’t launch before expiration of the respective SPC for adalimumab in October 2018

- PMLiVE

Boehringer builds evidence base for its Humira biosimilar

Cyltezo shows clinical equivalence to AbbVie's blockbuster in a late-stage trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links